| Today, the European pharmaceutical market is witnessing a deeper generic penetration as Governments accelerate their efforts towards encouraging the use of generic medicines, in order to contain the burgeoning healthcare costs arising from an upsurge in the ageing population.
The Company’s product portfolio in this market encompasses offerings in the Anti-Infectives, Cardiovascular and NSAID segments. The accent is on leveraging the development, manufacturing and commercialization capabilities and offering complex products which provides a natural hedge against competition and price erosion.
Lupin launched its direct-to-market initiative in UK under its own label, during the year. Its flagship product Lisinopril has been well received and has achieved a market share of 15% in the first four months of product introduction.
Similarly the Company has initiated its business in France with the introduction of Cefpodoxime Proxetil tablets through multiple partners. The product has garnered over 50% market share within first few months of its launch in 2007 reflecting Company’s strength in product quality and marketing skills.
Recently the Company also initiated its business in Germany through the acquisition of Hormosan Pharma GmbH, a German Sales and Marketing generic Company. Hormosan, with total sales of Euro 6.8 million for the year ended December 2007, develops licenses and markets a range of generics in Germany. Hormosan has a complementary product portfolio with products in the Central Nervous System and Cardiovascular therapy segments. Hormosan has created a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector. For more information:
www.hormosan.de
| 
